Medication info
Cregojung 5 mg (Rosuvastatin Calcium)

Cregojung 5 mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Il Yang Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201801342 · Approved 2018.03.27 · Insurance code 641705430

Summary

Main use
Improvement of dyslipidemia; inhibition of the progression of atherosclerosis; prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this drug at 20 mg to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race : Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of this drug at a dose of 40 mg is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Il Yang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia; inhibition of the progression of atherosclerosis; prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is primarily used as an adjunct to diet for patients with primary hypercholesterolemia and mixed dyslipidemia. It is especially helpful in cases where dietary and exercise measures are insufficient to control cholesterol. It is also administered in conjunction with other treatments for patients with homozygous familial hypercholesterolemia. This medication helps lower total cholesterol and LDL cholesterol levels in patients with hypercholesterolemia, thereby delaying the progression of atherosclerosis. It is effective for pediatric patients with specific criteria for heterozygous familial hypercholesterolemia. Additionally, it is used in the treatment of primary dysbetalipoproteinemia. In some adult patients with high cardiovascular risk, it contributes to reducing the risk of stroke, myocardial infarction, and arterial revascularization. This medication is used to improve cholesterol levels and reduce the risk of cardiovascular diseases.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this drug at 20 mg to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race : Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of this drug at a dose of 40 mg is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, patients with an allergy to this medication, severe liver problems, muscle disorders, severe kidney impairment, women who are pregnant or breastfeeding, and fertile women who do not use adequate contraception should not be treated with this medication. Additionally, caution should be exercised when administering this medication to patients at high risk of muscle-related side effects. Risk factors include moderate to severe kidney dysfunction, hypothyroidism, family history of muscle disorders, excessive alcohol consumption, and concomitant use of certain medications. It is important to regularly monitor liver function and muscle health during treatment with this medication. If there are abnormal elevations in liver enzyme levels or symptoms such as muscle pain, weakness, or cramps, immediate consultation with a physician is necessary. This medication can interact with other drugs, so it is essential to inform healthcare providers about any other medications being taken. The risk of muscle damage may increase when used in combination with certain antibiotics, antifungals, immunosuppressants, and fibrate medications. Women who are pregnant or planning to become pregnant should not take this medication, and it should be avoided in breastfeeding women as well, due to potential risks to the fetus and infant. In case of overdose, there is no specific antidote, so one should seek immediate medical attention for appropriate treatment and monitoring. Lastly, this medication may rarely cause serious skin reactions or liver damage, so if symptoms such as rashes, jaundice, or severe fatigue occur, discontinuation of the medication and consultation with healthcare providers is necessary.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculomotor dysfunction, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, systemic pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from exposure to air and moisture. It is best to maintain the storage temperature between 1°C and 30°C at room temperature. This ensures the medication's effectiveness is preserved safely.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.